GDTC

CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002.

Wall Street analysts forecast GDTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDTC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CytoMed Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

CytoMed Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

CytoMed Therapeutics Ltd (GDTC) has 28 emplpoyees as of December 16 2025.

Today GDTC has the market capitalization of 18.77M USD.